Castle Biosciences CEO Derek J. Maetzold trims stake by 14,496 shares worth $512,445.26 - CSTL News | RalliesCastle Biosciences CEO Derek J. Maetzold trims stake by 14,496 shares worth $512,445.26
C
CSTL• Castle Biosciences CEO trims stake after option exercise and share sales
- Castle Biosciences CEO Derek J. Maetzold exercised stock options for 8,580 shares at $2.39 on Sept. 21, 2026.
- He sold 8,580 shares at a weighted-average $35.33, cutting his direct stake to 21,479 shares.
- Separate sales of 3,198 shares and 2,718 shares were reported from trusts tied to Maetzold at $35.33.
•
